ARPO Aerpio Pharmaceuticals Inc

DGAP-News: Dorsett Wanchai, Hong Kong Offers 50% OFF All Executive Suites

DGAP-News: Dorsett Wanchai, Hong Kong / Key word(s): Miscellaneous
Dorsett Wanchai, Hong Kong Offers 50% OFF All Executive Suites (news with additional features)

07.11.2018 / 06:54
The issuer is solely responsible for the content of this announcement.


Dorsett Wanchai, Hong Kong Offers 50% OFF All Executive Suites

HONG KONG, CHINA - - 7 November 2018 - A lavish holiday in Hong Kong doesn't always have to burn a hole in your pocket. With Dorsett Wanchai's 50% off all suites deal, travel like a king or queen and be pampered by world-class hospitality while paying only half price for one of the most exquisite suites in Hong Kong. This deal is only available on the official hotel for book-and-stay periods between 20 November 2018 and 31 March 2019*.

Stay Vibrant. Stay at Dorsett Wanchai's Award-winning Theme Suites
Staying true to its brand promise - Stay Vibrant, the Dorsett Wanchai, Hong Kong, a 4-star contemporary offers a collection of exquisite theme suites:

The is decorated with marine elements, turning a living space into a marine park for a family to "live" in an undersea world. This 48 sq. m. suite features a semi-equipped pantry, a living area with a sofa bed, a dining area, and a separate bedroom fitted with a comfy king-size bed, as well as a spacious bathroom with bathtub and standing shower.

The , on the other hand, ensures family and leisure travellers' entertainment needs are met with perfection with Sony's latest gadgets. And for business travellers who long for a relaxed atmosphere after a full day's work, the is just the thing for those tired muscles.

Then there is the which is for those who enjoy the thrill of racing. The highlight of the Jockey Suite is the unobstructed racecourse view. If guests wish to visit the racetrack on racing nights (Wednesdays), they will be given a free "Happy Wednesday" Pack with free admission ticket, free drink, and a gift shop voucher.

For travellers who are believers in 'Active Wellness', the , is specially designed with their beauty needs in mind. A stay at the suite includes the following beauty perks:

- A set of 4-piece travel-sized skincare products

- Free use of high-tech beauty devices: 42 C Mobile Skin Therapist and 1-touch Intelligent Eye Therapist

- Free use of the Osim full body massage chair

PLUS

- 2-time complimentary hand treatment (30-minute) and 1- time complimentary Glycel signature facial treatment (75-minute)

And ONE of the following treatments:

- 1-time eye treatment (15-minute)

- 1-time detoxifying body massage (30-minute)

*Blackout dates apply and confirmation is subject to availability.

Media enquiries:
Jowie Wong | Director of Communications |


Additional features:

Document:
Document title: Banner


07.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


742331  07.11.2018 

fncls.ssp?fn=show_t_gif&application_id=742331&application_name=news&site_id=research_pool
EN
07/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch